- Home
- GEVO vs ABEO Comparison
GEVO vs ABEO Comparison
Compare GEVO & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEVO
- ABEO
- Stock Information
- Founded
- GEVO 2005
- ABEO 1974
- Country
- GEVO United States
- ABEO United States
- Employees
- GEVO N/A
- ABEO N/A
- Industry
- GEVO Major Chemicals
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- GEVO Industrials
- ABEO Health Care
- Exchange
- GEVO Nasdaq
- ABEO Nasdaq
- Market Cap
- GEVO 246.8M
- ABEO 256.9M
- IPO Year
- GEVO 2011
- ABEO 1980
- Fundamental
- Price
- GEVO $1.34
- ABEO $5.83
- Analyst Decision
- GEVO Buy
- ABEO Strong Buy
- Analyst Count
- GEVO 2
- ABEO 6
- Target Price
- GEVO $7.58
- ABEO $18.00
- AVG Volume (30 Days)
- GEVO 3.7M
- ABEO 976.0K
- Earning Date
- GEVO 08-07-2025
- ABEO 08-11-2025
- Dividend Yield
- GEVO N/A
- ABEO N/A
- EPS Growth
- GEVO N/A
- ABEO N/A
- EPS
- GEVO N/A
- ABEO N/A
- Revenue
- GEVO $42,034,000.00
- ABEO N/A
- Revenue This Year
- GEVO $1,043.01
- ABEO N/A
- Revenue Next Year
- GEVO $13.55
- ABEO $323.51
- P/E Ratio
- GEVO N/A
- ABEO N/A
- Revenue Growth
- GEVO 145.38
- ABEO N/A
- 52 Week Low
- GEVO $0.48
- ABEO $3.93
- 52 Week High
- GEVO $3.39
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- GEVO 60.70
- ABEO 45.53
- Support Level
- GEVO $1.19
- ABEO $6.10
- Resistance Level
- GEVO $1.41
- ABEO $6.24
- Average True Range (ATR)
- GEVO 0.08
- ABEO 0.29
- MACD
- GEVO 0.02
- ABEO -0.09
- Stochastic Oscillator
- GEVO 80.65
- ABEO 4.26
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.